Solventum Stock Outlook: Is Wall Street Bullish or Bearish?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 16 2025
0mins
Should l Buy PIPR?
Source: NASDAQ.COM
Company Overview and Stock Performance: Solventum Corporation, a healthcare company based in Minnesota with a market cap of $12.3 billion, has seen its stock outperform the broader market, rising 16.8% over the past year compared to the S&P 500's 11.5% gain. The company reported better-than-expected Q1 2025 results, with sales of $2.1 billion and an adjusted EPS of $1.34.
Analyst Ratings and Future Expectations: Analysts maintain a consensus rating of "Hold" for SOLV stock, with one "Strong Buy," eight "Holds," and one "Strong Sell." Despite expectations of a nearly 16.9% decline in adjusted EPS for fiscal 2025, Solventum has raised its organic sales growth forecast, boosting investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PIPR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PIPR
Wall Street analysts forecast PIPR stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 321.320
Low
386.00
Averages
386.00
High
386.00
Current: 321.320
Low
386.00
Averages
386.00
High
386.00
About PIPR
Piper Sandler Companies is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the United States and internationally. The Company operates in one segment, providing investment banking services, institutional sales and trading services for various equity and fixed income products, and research services. It provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. The Company operates alternative asset management funds in merchant banking and healthcare in order to invest firm capital and to manage capital from outside investors. It offers both equity and fixed income advisory and trade execution services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reasons Tech Stocks Might Underperform as Market Rally Expands Beyond AI
- AI Fears Impacting Stocks: Concerns about artificial intelligence are affecting tech-related stocks, indicating a shift in market sentiment.
- Sector's Future Uncertain: While the tech sector may still have potential, it appears it will need to share attention with other emerging trends.
See More
Analyst Reiterates Bullish Stance on Edgewise Stock
- Analyst Recommendation: Yasmeen Rahimi from Piper Sandler reiterated her overweight rating on Edgewise Therapeutics, setting a $51 price target, which contributed to a 4% stock increase, significantly outperforming the S&P 500's 0.5% rise.
- Clinical Trial Progress: Edgewise's cardiovascular drug candidate EDG-7500 is currently in Phase 2 clinical trials, with results expected in Q2 of this year, and if approved, it will provide an innovative solution for hypertrophic cardiomyopathy, enhancing market competitiveness.
- Market Potential: Rahimi considers Edgewise one of Piper Sandler's best stock picks for this year, based on its leading cardiovascular drug development and the potential of other pipeline projects, indicating strong prospects in the biotech sector.
- Muscle Development Treatment: In addition to cardiovascular drugs, Edgewise is advancing Sevasemten, a treatment for muscular dystrophy, showcasing the company's research capabilities and market opportunities across multiple therapeutic areas.
See More
Analyst Reiterates Bullish Stance on Edgewise
- Analyst Recommendation: Yasmeen Rahimi from Piper Sandler reiterated her buy rating on Edgewise Therapeutics (NASDAQ: EWTX) with a price target of $51 per share, demonstrating strong confidence in the company and likely attracting more investor interest.
- Stock Price Surge: Following the analyst's positive assessment, Edgewise's stock rose by 4% on Monday, significantly outperforming the S&P 500's 0.5% increase, reflecting market recognition of the company's potential.
- Clinical Trial Progress: Edgewise's cardiovascular drug candidate, EDG-7500, is currently in Phase 2 clinical trials, with results expected this quarter; approval could provide the company with a significant competitive edge in the market.
- Pipeline Potential: In addition to EDG-7500, Rahimi highlighted that Edgewise has solid potential in other drug developments, particularly with Sevasemten for muscular dystrophy, further enhancing the company's market outlook.
See More
Braze Stock Price Target Cut Again, Analyst Sees Growth Potential
- Price Target Reduction: Stifel analyst Parker Lane cut Braze's price target from $45 to $40 while maintaining a buy rating, indicating recognition of the company's future growth opportunities.
- Investor Sentiment Decline: Braze's stock fell 0.7% in today's trading, recovering from an earlier decline of 5.2%, reflecting a cautious market attitude towards the tech stock.
- Improved Financial Performance: In Q3 2025, Braze reported a 25% year-over-year revenue increase with free cash flow of $17.8 million, a significant improvement compared to negative free cash flow of $14.2 million during the same period last year.
- Valuation Appeal: Braze shares are currently trading at 2.7 times sales, a discount to the five-year average price-to-sales ratio of 6.2, indicating attractive investment opportunities in the artificial intelligence sector.
See More
Stifel Analyst Lowers Braze Price Target to $40
- Price Target Cut: Stifel analyst Parker Lane has lowered the price target for Braze stock from $45 to $40 while maintaining a buy rating, indicating a decline in investor sentiment that has led to a drop in stock price despite the company's growth potential.
- Strong Financial Performance: In Q3 2025, Braze reported a 25% year-over-year revenue increase, achieving $17.8 million in free cash flow compared to a negative $14.2 million during the same period last year, highlighting significant financial improvement.
- Attractive Market Valuation: With shares trading at 2.7 times sales, a discount to the five-year average price-to-sales ratio of 6.2, Braze stock is positioned as an appealing option for investors looking for exposure to artificial intelligence.
- Investor Recommendations: Although Braze was not included in the Motley Fool Stock Advisor's top ten stock picks, analysts emphasize the company's strong fundamentals and growth opportunities, suggesting that investors focus on these aspects rather than solely on price targets.
See More
Piper Sandler Q4 2025 Earnings Highlights
- Record Performance: Piper Sandler achieved adjusted net revenues of $635 million in Q4 2025, reflecting a 27% year-over-year increase and a 27.2% operating margin, demonstrating strong market execution and growth potential.
- Strong Advisory Business: The company reported over $1 billion in advisory revenues, accounting for 55% of total net revenues, marking its sustained leadership in the advisory sector and laying the groundwork for future revenue growth.
- Increased Shareholder Returns: In 2025, Piper Sandler returned $239 million to shareholders through stock buybacks and dividends, and the Board approved a 4-for-1 stock split to enhance liquidity and attract a broader range of investors.
- Optimistic Outlook: Management expressed a positive outlook for 2026, anticipating continued growth in advisory revenues and setting a target to exceed $2 billion in annual investment banking revenues in the coming years, reflecting confidence in market opportunities.
See More
Reasons Tech Stocks Might Underperform as Market Rally Expands Beyond AI
- AI Fears Impacting Stocks: Concerns about artificial intelligence are affecting tech-related stocks, indicating a shift in market sentiment.
- Sector's Future Uncertain: While the tech sector may still have potential, it appears it will need to share attention with other emerging trends.
See More
Analyst Reiterates Bullish Stance on Edgewise Stock
- Analyst Recommendation: Yasmeen Rahimi from Piper Sandler reiterated her overweight rating on Edgewise Therapeutics, setting a $51 price target, which contributed to a 4% stock increase, significantly outperforming the S&P 500's 0.5% rise.
- Clinical Trial Progress: Edgewise's cardiovascular drug candidate EDG-7500 is currently in Phase 2 clinical trials, with results expected in Q2 of this year, and if approved, it will provide an innovative solution for hypertrophic cardiomyopathy, enhancing market competitiveness.
- Market Potential: Rahimi considers Edgewise one of Piper Sandler's best stock picks for this year, based on its leading cardiovascular drug development and the potential of other pipeline projects, indicating strong prospects in the biotech sector.
- Muscle Development Treatment: In addition to cardiovascular drugs, Edgewise is advancing Sevasemten, a treatment for muscular dystrophy, showcasing the company's research capabilities and market opportunities across multiple therapeutic areas.
See More
Analyst Reiterates Bullish Stance on Edgewise
- Analyst Recommendation: Yasmeen Rahimi from Piper Sandler reiterated her buy rating on Edgewise Therapeutics (NASDAQ: EWTX) with a price target of $51 per share, demonstrating strong confidence in the company and likely attracting more investor interest.
- Stock Price Surge: Following the analyst's positive assessment, Edgewise's stock rose by 4% on Monday, significantly outperforming the S&P 500's 0.5% increase, reflecting market recognition of the company's potential.
- Clinical Trial Progress: Edgewise's cardiovascular drug candidate, EDG-7500, is currently in Phase 2 clinical trials, with results expected this quarter; approval could provide the company with a significant competitive edge in the market.
- Pipeline Potential: In addition to EDG-7500, Rahimi highlighted that Edgewise has solid potential in other drug developments, particularly with Sevasemten for muscular dystrophy, further enhancing the company's market outlook.
See More
Braze Stock Price Target Cut Again, Analyst Sees Growth Potential
- Price Target Reduction: Stifel analyst Parker Lane cut Braze's price target from $45 to $40 while maintaining a buy rating, indicating recognition of the company's future growth opportunities.
- Investor Sentiment Decline: Braze's stock fell 0.7% in today's trading, recovering from an earlier decline of 5.2%, reflecting a cautious market attitude towards the tech stock.
- Improved Financial Performance: In Q3 2025, Braze reported a 25% year-over-year revenue increase with free cash flow of $17.8 million, a significant improvement compared to negative free cash flow of $14.2 million during the same period last year.
- Valuation Appeal: Braze shares are currently trading at 2.7 times sales, a discount to the five-year average price-to-sales ratio of 6.2, indicating attractive investment opportunities in the artificial intelligence sector.
See More
Stifel Analyst Lowers Braze Price Target to $40
- Price Target Cut: Stifel analyst Parker Lane has lowered the price target for Braze stock from $45 to $40 while maintaining a buy rating, indicating a decline in investor sentiment that has led to a drop in stock price despite the company's growth potential.
- Strong Financial Performance: In Q3 2025, Braze reported a 25% year-over-year revenue increase, achieving $17.8 million in free cash flow compared to a negative $14.2 million during the same period last year, highlighting significant financial improvement.
- Attractive Market Valuation: With shares trading at 2.7 times sales, a discount to the five-year average price-to-sales ratio of 6.2, Braze stock is positioned as an appealing option for investors looking for exposure to artificial intelligence.
- Investor Recommendations: Although Braze was not included in the Motley Fool Stock Advisor's top ten stock picks, analysts emphasize the company's strong fundamentals and growth opportunities, suggesting that investors focus on these aspects rather than solely on price targets.
See More
Piper Sandler Q4 2025 Earnings Highlights
- Record Performance: Piper Sandler achieved adjusted net revenues of $635 million in Q4 2025, reflecting a 27% year-over-year increase and a 27.2% operating margin, demonstrating strong market execution and growth potential.
- Strong Advisory Business: The company reported over $1 billion in advisory revenues, accounting for 55% of total net revenues, marking its sustained leadership in the advisory sector and laying the groundwork for future revenue growth.
- Increased Shareholder Returns: In 2025, Piper Sandler returned $239 million to shareholders through stock buybacks and dividends, and the Board approved a 4-for-1 stock split to enhance liquidity and attract a broader range of investors.
- Optimistic Outlook: Management expressed a positive outlook for 2026, anticipating continued growth in advisory revenues and setting a target to exceed $2 billion in annual investment banking revenues in the coming years, reflecting confidence in market opportunities.
See More
